We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Predicts Sickle Cell Severity

By LabMedica International staff writers
Posted on 15 Mar 2012
A simple blood test has been devised that can predict whether sickle cell patients are at high risk for painful complications of the disease. More...


The device measures how well blood samples flow through a microfluidic device, which could help doctors monitor sickle cell patients and determine the best course of treatment.

Scientists at Massachusetts Institute of Technology (MIT; Cambridge, MA, USA), collaborating with others, have developed a microfluidic system to measure changes in sickle cell blood flow after deoxygenation. The system included a microfluidic device with a capillary-sized channel that was diffusively coupled to a gas reservoir. This system allowed control over many parameters that mimic physiological conditions during vaso-occlusion, including channel size, blood pressure, and oxygen concentration.

The investigators compared blood samples taken from sickle cell patients who had or had not made an emergency trip to the hospital or received a blood transfusion within the previous 12 months. Tests were carried out with blood samples from 23 patients with severe disease and 6 patients with benign disease. They directed blood through a microchannel and lowered its oxygen concentration, which triggers sickle cells to jam and block blood flow. These conditions can produce a vaso-occlusive crisis.

Blood samples from patients with more benign disease showed a significantly slower decrease in the conductance after deoxygenation. Oxygen concentration of the gas phase was measured with a fiber optic sensor (Ocean Optics, Dunedin, FL, USA) connected to the outlet of the gas reservoir. No other existing measures of blood properties, including concentration of red blood cells, fraction of altered hemoglobin or white blood cell count, can make this kind of prediction of severe disease.

The authors concluded that the strong correlation between blood rheodynamics and the clinical outcomes in the study population provides a valuable tool for scientific discovery, drug development, and possibly for patient monitoring and clinical decision-making in sickle cell disease. The scientists have applied for a patent on the technology and are now working on developing it as a diagnostic tool. The study was published on February 29, 2012, in the journal Science Translational Medicine.

Related Links:

Massachusetts Institute of Technology
Ocean Optics



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Repetitive Pipette
VWR® Stepper Pro
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.